News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
227,620 Results
Type
Article (11145)
Company Profile (25)
Press Release (216450)
Section
Business (75861)
Career Advice (1046)
Deals (14474)
Drug Delivery (28)
Drug Development (34938)
Employer Resources (38)
FDA (5964)
Job Trends (5775)
News (128398)
Policy (9625)
Tag
Academia (748)
Africa (276)
Allergies (27)
Alliances (10028)
Alzheimer's disease (456)
Antibody-drug conjugate (ADC) (26)
Approvals (5956)
Arizona (34)
Asia (13843)
Australia (2110)
Bankruptcy (92)
Best Places to Work (4856)
Biosimilars (26)
C2C Services and Suppliers (21135)
California (714)
Canada (361)
Cancer (176)
Career advice (826)
CAR-T (21)
Cell therapy (50)
China (50)
Clinical research (28403)
Collaboration (39)
Colorado (21)
Compensation (40)
Connecticut (18)
COVID-19 (898)
Cystic fibrosis (20)
Data (88)
Diabetes (31)
Diagnostics (2103)
Drug pricing (19)
Earnings (53316)
Employer resources (32)
Europe (32300)
Events (35688)
FDA (6038)
Florida (88)
Funding (21)
Gene therapy (33)
GLP-1 (257)
Government (1363)
Healthcare (7217)
Hotbed/Location (157771)
Illinois (76)
Indiana (52)
Infectious disease (905)
Inflammatory bowel disease (33)
Interviews (190)
IPO (9040)
Job creations (958)
Job search strategy (736)
Kansas (40)
Layoffs (130)
Legal (1679)
Liver cancer (29)
Lung cancer (45)
Maine (25)
Manufacturing (19)
Maryland (119)
Massachusetts (574)
Medical device (4978)
Medtech (4978)
Mergers & acquisitions (5401)
Metabolic disorders (113)
Michigan (33)
Minnesota (68)
Neuroscience (505)
New Hampshire (33)
New Jersey (193)
New York (225)
NextGen Class of 2024 (2221)
Non-profit (1463)
North Carolina (191)
Northern California (352)
Obesity (71)
Ohio (34)
Opinion (56)
Peanut (25)
Pennsylvania (235)
People (8816)
Phase I (7628)
Phase II (12218)
Phase III (10827)
Pipeline (85)
Postmarket research (1254)
Preclinical (2536)
Rare diseases (40)
Real estate (1138)
Regulatory (6891)
Research institute (714)
Resumes & cover letters (196)
South America (422)
Southern California (320)
Startups (784)
Texas (75)
United States (3025)
Vaccines (193)
Washington State (105)
Weight loss (63)
Date
Last 7 days (218)
Last 30 days (1222)
Last 365 days (17429)
2024 (11653)
2023 (17836)
2022 (21574)
2021 (22719)
2020 (20355)
2019 (17978)
2018 (12805)
2017 (12139)
2016 (10390)
2015 (12659)
2014 (9071)
2013 (6615)
2012 (7212)
2011 (7510)
2010 (6715)
227,620 Results for "4".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Philips completes cancellation of 4.4 million shares
Royal Philips announced that it has completed the cancellation of 4,437,164 of its shares.
June 19, 2024
·
1 min read
Drug Development
4DMT Unveils More Positive Data for Wet AMD Candidate
Mid-stage data for
4D Molecular Therapeutics’ wet AMD drug 4D-150 show improvements in visual acuity, reduced injection rate and encouraging safety data.
July 17, 2024
·
2 min read
·
Tyler Patchen
Biotech Bay
4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy
4D Molecular Therapeutics today announced U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug Application (IND) for 4D-175, an R100 vector-based intravitreal genetic medicine, for the treatment of patients with GA.
June 24, 2024
·
7 min read
Deals
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 3, 2024
X4 Pharmaceuticals today announced that, effective on May 31, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc.
June 3, 2024
·
1 min read
Drug Development
4Moving Biotech announces successful results from its Lasare Phase I 4P004 Clinical Trial intraarticular Liraglutide for knee osteoarthritis patients
4Moving Biotech, a spin-off of 4P-Pharma committed to developing first-in-class treatments to modify the natural course of knee osteoarthritis, announces the successful achievement of the Phase 1 Lasare trial in knee osteoarthritis patients using 4P004.
June 10, 2024
·
3 min read
BioMidwest
Humhealth Unveils Remote Patient Monitoring With Advanced 4G Device Configuration and 4G Watch
Humhealth, a leading provider of innovative remote care solutions, has the capability to integrate with an advanced 4G Telehealth Gateway Hub and 4G vital monitoring devices.
May 1, 2024
·
3 min read
Deals
CNS Pharmaceuticals Announces Reverse Stock Split - June 4, 2024
CNS Pharmaceuticals, Inc. today announced a 1-for-50 reverse split of its common stock, effective at 4:01 PM ET on June 4, 2024.
June 3, 2024
·
3 min read
Pharm Country
Tiziana Receives $3.4 Million in Non-Dilutive Funding
Tiziana Life Sciences, Ltd., a biotechnology company developing breakthrough therapies in neurodegenerative disease secondary to active neuroinflammatory processes announced that it had received non-dilutive funding of $3.4 million and issued a corporate update video available here.
June 28, 2024
·
2 min read
Biotech Bay
4DMT to Participate in Upcoming Investor Conferences - June 3, 2024
4D Molecular Therapeutics today announced that management will participate in fireside chats at upcoming investor conferences in June.
June 3, 2024
·
2 min read
Drug Development
Novo Nordisk Continues Manufacturing Spending Spree With $4.1B Investment
Novo Nordisk on Monday announced it is boosting its manufacturing capabilities with a $4.1 billion commitment to construct a second fill and finishing facility in Clayton, North Carolina.
June 25, 2024
·
2 min read
·
Tristan Manalac
1 of 22,762
Next
